Affimed (AFMD) News Today $1.15 +0.07 (+6.48%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Analyst revises Affimed Therapeutics stock price target amid AFM24 trial progressionDecember 20, 2024 | uk.investing.comAffimed price target lowered to $11 from $15 at Wells FargoDecember 19, 2024 | markets.businessinsider.comAffimed (AFMD) Gets a Buy from Truist FinancialDecember 19, 2024 | markets.businessinsider.comAffimed’s AFM24/atezolizumab combination shows positive results in NSCLC trialDecember 18, 2024 | markets.businessinsider.comAffimed price target lowered to $7 from $10 at H.C. WainwrightDecember 18, 2024 | tipranks.comAffimed’s Promising Clinical Update on NSCLC TreatmentDecember 18, 2024 | markets.businessinsider.comAffimed Shares Fall 32% on Clinical UpdateDecember 18, 2024 | finance.yahoo.comAffimed stock plunges 23% on AFM24 study updateDecember 18, 2024 | msn.comAffimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)December 17, 2024 | markets.businessinsider.comAffimed Reports Positive Data From AFM24-102 Trial In Heavily Pretreated NSCLC PatientsDecember 17, 2024 | markets.businessinsider.comAffimed price target lowered to $15 from $20 at Wells FargoDecember 12, 2024 | tipranks.comAffimed reports ‘promising’ Phase 1 efficacy, safety data for AFM28December 9, 2024 | tipranks.comAffimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)December 9, 2024 | globenewswire.comAffimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung CancerDecember 9, 2024 | globenewswire.comAffimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) PatientsDecember 8, 2024 | globenewswire.comAffimed Announces RMAT Designation To Combination Therapy Of ICE Acimtamig And AB101December 5, 2024 | markets.businessinsider.comAffimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)December 5, 2024 | globenewswire.comIs Affimed N.V. (AFMD) the Best German Stock to Buy Now?November 19, 2024 | msn.comCantor Fitzgerald Reiterates "Overweight" Rating for Affimed (NASDAQ:AFMD)Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Affimed in a report on Tuesday.November 19, 2024 | marketbeat.comPromising Clinical Developments and Data Catalysts Position Affimed for Strong Future ProspectsNovember 17, 2024 | markets.businessinsider.comAffimed price target lowered to $4 from $5 at StifelNovember 17, 2024 | markets.businessinsider.comStifel Nicolaus Cuts Affimed (NASDAQ:AFMD) Price Target to $4.00Stifel Nicolaus cut their target price on Affimed from $5.00 to $4.00 and set a "hold" rating on the stock in a report on Friday.November 15, 2024 | marketbeat.comAffimed N.V. (NASDAQ:AFMD) Q3 2024 Earnings Call TranscriptNovember 15, 2024 | insidermonkey.comHC Wainwright Reiterates Buy Rating for Affimed (NASDAQ:AFMD)HC Wainwright reiterated a "buy" rating and set a $10.00 price objective on shares of Affimed in a report on Friday.November 15, 2024 | marketbeat.comAffimed Faces Growing Losses Amid Financial StrugglesNovember 15, 2024 | markets.businessinsider.comAffimed N.V. (AFMD) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comAffimed Reports Third Quarter 2024 Financial Results & Business UpdateNovember 14, 2024 | globenewswire.comA Look Ahead: Affimed's Earnings ForecastNovember 13, 2024 | benzinga.comAffimed Q3 2024 Earnings PreviewNovember 13, 2024 | msn.comAffimed (AFMD) Set to Announce Earnings on ThursdayAffimed (NASDAQ:AFMD) will be releasing earnings before the market opens on Thursday, November 14, Zacks reports.November 7, 2024 | marketbeat.comAffimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024November 6, 2024 | globenewswire.comAffimed (NASDAQ:AFMD) Share Price Passes Above Fifty Day Moving Average - Time to Sell?Affimed (NASDAQ:AFMD) Stock Passes Above 50 Day Moving Average - Time to Sell?November 6, 2024 | marketbeat.comAffimed (NASDAQ:AFMD) Given Average Rating of "Buy" by AnalystsShares of Affimed (NASDAQ:AFMD - Get Free Report) have received a consensus rating of "Buy" from the four ratings firms that are presently covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a buy recommendation. The average 12-month target price among analysOctober 28, 2024 | marketbeat.com683 Capital Management, LLC Expands Stake in Affimed NVOctober 24, 2024 | gurufocus.comAffimed (NASDAQ:AFMD) Given Average Rating of "Buy" by BrokeragesAffimed (NASDAQ:AFMD - Get Free Report) has earned a consensus rating of "Buy" from the four research firms that are currently covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a buy rating. The average 12-month target price among brokerages that have issuOctober 3, 2024 | marketbeat.comTruist Financial Sticks to Its Buy Rating for Affimed (AFMD)September 24, 2024 | markets.businessinsider.comAffimed N.V. (A28A.F)September 11, 2024 | sg.finance.yahoo.comAffimed to Present at the Cantor Global Healthcare Conference 2024September 10, 2024 | globenewswire.comAffimed (NASDAQ:AFMD) Earns Overweight Rating from Cantor FitzgeraldCantor Fitzgerald reiterated an "overweight" rating on shares of Affimed in a report on Monday.September 9, 2024 | marketbeat.comAffimed (NASDAQ:AFMD) Receives Average Rating of "Buy" from AnalystsShares of Affimed (NASDAQ:AFMD - Get Free Report) have received a consensus recommendation of "Buy" from the four ratings firms that are covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers thaSeptember 8, 2024 | marketbeat.comAffimed N.V. (NASDAQ:AFMD) Q2 2024 Earnings Call TranscriptSeptember 7, 2024 | msn.comBuy Rating Justified by Promising Clinical Data and Solid Progress in Affimed’s Drug DevelopmentsSeptember 6, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Affimed (NASDAQ:AFMD)HC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of Affimed in a report on Friday.September 6, 2024 | marketbeat.comAffimed Reports Second Quarter 2024 Financial Results & Business UpdateSeptember 5, 2024 | markets.businessinsider.comAffimed N.V. (AFMD) Q2 2024 Earnings Call TranscriptSeptember 5, 2024 | seekingalpha.comAffimed Appoints Shawn M. Leland as Chief Executive OfficerSeptember 3, 2024 | globenewswire.comAffimed (AFMD) Scheduled to Post Earnings on ThursdayAffimed (NASDAQ:AFMD) will be releasing earnings before the market opens on Thursday, September 5, Zacks reports.August 30, 2024 | marketbeat.comAffimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024August 29, 2024 | globenewswire.comAffimed (NASDAQ:AFMD) Stock Price Crosses Below 200 Day Moving Average of $5.35Affimed (NASDAQ:AFMD) Share Price Passes Below Two Hundred Day Moving Average of $5.35August 24, 2024 | marketbeat.comShort Interest in Affimed (NASDAQ:AFMD) Decreases By 19.3%Affimed (NASDAQ:AFMD - Get Free Report) was the target of a significant drop in short interest in the month of July. As of July 31st, there was short interest totalling 783,900 shares, a drop of 19.3% from the July 15th total of 971,500 shares. Based on an average daily trading volume, of 694,200 shares, the short-interest ratio is presently 1.1 days. Approximately 6.0% of the company's stock are short sold.August 16, 2024 | marketbeat.com Get Affimed News Delivered to You Automatically Sign up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter. Email Address AFMD Media Mentions By Week AFMD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AFMD News Sentiment▼1.000.44▲Average Medical News Sentiment AFMD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AFMD Articles This Week▼02▲AFMD Articles Average Week Get Affimed News Delivered to You Automatically Sign up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PYRGF News Today AADI News Today QNCX News Today IKNA News Today PMVP News Today CLSD News Today AVTX News Today ANVS News Today GNTA News Today MURA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AFMD) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Affimed Please log in to your account or sign up in order to add this asset to your watchlist. Share Affimed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AFMD Stock Alerts